Ken Griffin Genfit S.A. Call Options Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding GNFT
# of Institutions
9Shares Held
209KCall Options Held
0Put Options Held
0-
Israel Englander Millennium Management LLC | New York, Ny131KShares$540,3950.0% of portfolio
-
Morgan Stanley New York, NY25.5KShares$104,8870.0% of portfolio
-
Old Mission Capital LLC22.2KShares$91,3980.0% of portfolio
-
Optiver Holding B.V. Amsterdam, P713.2KShares$54,0670.0% of portfolio
-
Ubs Group Ag3.12KShares$12,8140.0% of portfolio
About Genfit S.A.
- Ticker GNFT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,815,500
- Market Cap $205M
- Description
- Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagno...